Revvity, Inc. (RVTY)

Over the past six months, Revvity's stock has trended downwards by 6.65%. Key events impacting the stock price include earnings reports, product launches and collaborations, share repurchases and dividends, and analyst sentiment. Q1 2025 financial results showed better-than-expected revenue and adjusted EPS, with sales up 2.3% year-on-year to $664.8 million. Q2 2025 financial results also beat Wall Street's revenue expectations, with sales up 4.1% year-on-year to $720.3 million. Revvity unveiled new AI software offering to transform preclinical imaging analysis and collaborated with Profluent to launch AI-enhanced Adenine Deaminase Pin-point Base Editing Systems. Revvity repurchased 154 million shares in Q1 2025, representing a 6% decline in total shares outstanding since mid-2023. As of October 2025, analysts have a "Moderate Buy" consensus rating for RVTY, with an average price target of $118.57.

While specific recurring seasonal patterns in demand for Revvity's products and services are not explicitly detailed, recent reports indicate some fluctuations in demand. In the first quarter of 2025, the company experienced "unforeseen choppiness in demand from US academic customers," which primarily affected its life science instruments. Overall, Revvity has faced periods of "weak demand," with its revenue declining by 4.3% annually over the last two years. For 2025, Revvity projected low revenue growth of 2.54%, indicating a continued period of soft demand in the short term.

Revvity, Inc. is a global leader in health sciences solutions, technologies, expertise, and services, delivering complete workflows from discovery to development, and diagnosis to cure. The company operates in the Healthcare sector, specifically in the Diagnostics & Research and Biotechnology: Laboratory Analytical Instruments industries. Revvity's business is structured around two main segments: Life Sciences and Diagnostics, providing advanced tools and technologies for research and delivering solutions for clinical and industrial applications. Major products and offerings include instruments, reagents, informatics, software, subscriptions, detection and imaging technologies, warranties, training, and DNA sequencing services. Revvity serves a diverse customer base, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. Founded in 1937, formerly known as PerkinElmer, Inc., changing its name to Revvity, Inc. in April 2023, reflecting its focus on innovation in life sciences.

Headquartered in Waltham, Massachusetts, U.S., Revvity, Inc. has a significant global presence, marketing its products and services in more than 160 countries worldwide.

In the past year, Revvity's brand reputation appears to be generally positive, driven by its focus on innovation and strategic collaborations. The company has actively launched new products and formed partnerships, which typically enhance its standing in the health sciences market. Analyst ratings reflect a positive sentiment, with a consensus of "Moderate Buy" for the stock.

Revvity, Inc. is predominantly owned by institutional shareholders, who hold 98.57% of the stock. The company has 1087 institutional owners and shareholders holding a total of 140,259,941 shares. Major institutional owners include T. Rowe Price Investment Management, Inc., Vanguard Group Inc, and BlackRock, Inc. Individual insider ownership accounts for 2.74% of the company, with the largest individual Revvity shareholder being Alexis P. Michas.